Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Takeda Pharmaceutical Company v. Torrent Pharmaceuticals Ltd., No. 20-1552 (Fed. Cir. Feb. 16, 2021)

Affirmed
Invalidity (§ 102/§ 103) Summary Judgment
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 20-1552
Also Docketed
No. 20-1598 (consolidated; same document)
Decided
February 16, 2021
Judge
Chen, J.
Document
Nonprecedential Opinion
Length
8 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Torrent and Indoco (collectively, Appellants) appeal from the district court’s final judgment on Appellants’ in- validity challenges to claims 4 and 12 of U.S. Patent No. 7,807,689, owned by Takeda.1 See Takeda Pharm. Co. Ltd. v. Torrent Pharm. Ltd., No. 2:17-cv-03186-SRC-CLW, 2020 WL 549594 , at *26 (D.N.J. Feb. 4, 2020) (Takeda). The claims at issue are directed to alogliptin, a uracil-contain- ing DPP-IV inhibitor useful for treating type II diabetes, and pharmaceutical salts thereof.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error